STAT+: Cochrane review reignites Alzheimer’s amyloid wars
Another Elevidys trial, FDA reconsiders peptides, and other biotech news from The Readout
health_news
STAT+: Pharmalittle: We’re reading about a review of Alzheimer’s drugs, FDA interest in compounded peptides, and more
The FDA will convene an outside panel of advisers to discuss whether to allow compounding pharmacies to manufacture certain peptides
Concierge Care for All: Yes, It Really Is That Simple
By MATTHEW HOLT & CLAUDE You’ll recall that a few weeks back I gave Claude some prompts and my entire corpus of work on THCB and asked it to write…
Is Social Media Addictive? What the Science Really Says
A Michigan State University expert examines whether social media meets clinical addiction standards and what research and the APA still need to resolve
STAT+: Novartis CEO joins Anthropic’s board
Revolution Medicines $2B fundraise, Structure's new hire hints at acquisition efforts, and more Readout biotech news
STAT+: Pharmalittle: We’re reading about FDA seeking more data on a Lilly obesity pill, a pharma 340B win, and more
The FDA asked Eli Lilly for more data on liver injury linked to its newly approved obesity pill, Foundayo
STAT+: Flawed study on the antidepressant Paxil came with a cautionary note — if you knew how to find it
When scientific journals publish expressions of concerns, they have an obligation to do so prominently, Ed Silverman writes.
STAT+: Congress returns to a packed health care agenda
The key health care issues we're watching as Congress returns from recess.
STAT+: FDA pressures drugmakers to report trial results
Ben Sasse on enrolling in Rev Med's drug trial, more ADC investment, and other biotech news from The Readout
STAT+: Pharmalittle: We’re reading about an FDA push for trial transparency, a Novo-OpenAI deal, and more
The FDA told more than 2,200 companies and researchers that they are required to report clinical trial results, or they may face fines